Core Viewpoint - The company, Adebiotech, has shown a stable performance in the medical device industry, with a notable increase in net profit despite a decline in capital inflow [1][2]. Company Overview - Adebiotech's main business includes tumor gene testing reagents, software, and supporting instruments, along with testing services and drug clinical research services [1]. - The company has received multiple national and industry honors, including "National High-tech Enterprise" and "National Enterprise Technology Center," highlighting its achievements in technological innovation [1]. Financial Performance - For the first half of 2025, the company reported revenue of 579 million yuan, a year-on-year increase of 6.69%, and a net profit of 189 million yuan, reflecting a year-on-year growth of 31.41% [2]. - The company's gross profit margin stands at 84.00% [2]. Market Position - As of August 15, Adebiotech's stock closed at 23.91 yuan, with a rolling price-to-earnings (PE) ratio of 31.20 times, while the average PE ratio in the medical device industry is 56.58 times [1][2]. - The company's total market capitalization is 9.362 billion yuan [1]. Capital Flow - On August 15, the company experienced a net outflow of 19.39 million yuan in principal funds, with a total outflow of 58.36 million yuan over the past five days [1].

7月29日，艾德生物今日收盘23.87元，下跌2.77%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到31.15倍，总市值93.46亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.46倍，行业中值37.74倍，艾德生物排 名第62位。 资金流向方面，7月29日，艾德生物主力资金净流出1048.80万元，近5日总体呈流入状态，5日共流入 3442.88万元。 厦门艾德生物医药科技股份有限公司的主营业务是肿瘤基因检测试剂、软件及配套仪器，并提供检测服 务及药物临床研究服务。公司的主要产品是检测试剂、软件及配套仪器。公司荣获多项国家级及行业荣 誉，包括"国家高新技术企业"、"国家企业技术中心"、"制造业单项冠军企业"、"国家知识产权示范企 业"、"专精特新小巨人企业"、"博士后科研工作站"等资质，并获批设立"国家发改委基因检测技术应用 示范中心"、"福建省肿瘤分子诊断企业工程技术研究中心"等。研发团队荣膺"全国工人先锋号"、研发 骨干荣获"全国劳动模范"光荣称号，进一步体现了公司在技术创新领域的卓越成就。 最新一期业绩显示，2025年半年报，公司实现营业收入5.79亿元，同比6. ...